Early Response to Vunakizumab at Week 2 Predicts Favourable Long‐Term Efficacy in Patients With Moderate‐To‐Severe Plaque Psoriasis: A Post Hoc Analysis of a Phase III , Randomised Controlled Trial
This study was a post hoc analysis of a Phase III trial (NCT04839016), which aims to investigate whether early response to vunakizumab can predict long‐term efficacy in plaque psoriasis patients. A total of 461 plaque psoriasis patients receiving vunakizumab treatment were included for analysis. Ear...
Saved in:
| Published in: | Immunology 2026-01 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Citations: | Items that this one cites |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|